-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
At the end of 2021, there are at least two major medical events that are of great concern to the industry.
One is that the results of a new round of medical insurance negotiations are about to be released, and the other is the progress of the sixth batch of special insulin procurement
.
According to industry sources, the results of the new round of medical insurance negotiations are expected to be announced at the end of this month
.
In recent days, the sixth batch of centralized drug procurement has also seen new developments
.
According to the news on November 26, the sixth batch of centralized procurement of drugs will officially enter the information disclosure stage
.
This centralized drug procurement involves 81 varieties of insulin products, involving Jiangsu Wanbang, Novo Nordisk, Tonghua Dongbao, Ganli Pharmaceutical, United Laboratories, Sanofi, Eli Lilly, Hefei Tianmai, Poland Baitong (domestic production The enterprise/sub-packaging plant is a total of 9 domestic and foreign enterprises including Harbin Yuheng Pharmaceutical/Hefei Yifan) and Yichang Dongyangguang
.
The 81 varieties will be divided into 6 purchase groups of mealtime human insulin, basal human insulin, premixed human insulin, mealtime insulin analogues, basal insulin analogues, and premixed insulin analogues
.
Enterprises in each procurement group that meet the qualifications for declaration shall declare according to the quotation unit, and there are a total of 11 quotation units
.
It is understood that these types of participating in centralized procurement are all marketed drugs that have obtained valid domestic registration approvals before November 14, 2021 (inclusive), and their quality meets the standards of relevant national departments.
Products produced in accordance with the requirements of relevant departments are eligible to participate.
This round of national mining
.
In addition, companies participating in the bidding also need to meet the requirements of this centralized procurement in terms of quality standards, production capacity, supply stability, and corporate credit
.
Zhongtai Securities mentioned in a research report that the bidding and quantity rules have fully borrowed some rules from the centralized procurement of chemical drugs and the centralized procurement of insulin in Wuhan, and at the same time fully considers the actual production capacity of the company to avoid some companies from paying less than the cost.
Malicious declaration of prices
.
In addition, according to the research report issued by Dongguan Securities, the 81 varieties collected this time, specifically, there are 43 second-generation insulins, accounting for 53%, and 38 third-generation insulins, accounting for 47%.
Mixed insulin product group (there are 18 varieties), the least is the two product groups of basal insulin and premixed insulin analogues, both have only 12 varieties
.
From a corporate perspective, local and foreign companies are basically the same, with 41 local companies and 40 foreign companies
.
This also means that in this centralized procurement, domestic insulin varieties will have fierce competition with imported varieties, among which the competition of second-generation and third-generation insulin may be more intense
.
According to data from Meinenet, the sales of terminal insulin and similar drugs in China's public medical institutions in 2020 will be close to 27 billion yuan, of which Novo Nordisk, Sanofi, and Eli Lilly have a combined market share of more than 70%
.
Among domestic pharmaceutical companies, Ganli Pharmaceutical, Tonghua Dongbao, United Laboratories, etc.
are the leading companies.
Among them, Ganli Pharmaceutical's insulin market share will exceed 10% in 2020
.
The industry generally believes that with the implementation of centralized insulin procurement, the market structure may be rewritten, foreign-funded companies no longer occupy most of the market share, and domestic insulin-based leading companies may benefit
.
For diabetic patients, the base of diabetic patients in China is very large.
Data shows that the number of diabetic patients in China has reached 129 million, accounting for about 10% of China's total population
.
As an important drug for the treatment of diabetes, the price of insulin is expected to be further reduced after collective procurement negotiations, which will reduce the burden of drug costs for diabetic patients
.
One is that the results of a new round of medical insurance negotiations are about to be released, and the other is the progress of the sixth batch of special insulin procurement
.
According to industry sources, the results of the new round of medical insurance negotiations are expected to be announced at the end of this month
.
In recent days, the sixth batch of centralized drug procurement has also seen new developments
.
According to the news on November 26, the sixth batch of centralized procurement of drugs will officially enter the information disclosure stage
.
This centralized drug procurement involves 81 varieties of insulin products, involving Jiangsu Wanbang, Novo Nordisk, Tonghua Dongbao, Ganli Pharmaceutical, United Laboratories, Sanofi, Eli Lilly, Hefei Tianmai, Poland Baitong (domestic production The enterprise/sub-packaging plant is a total of 9 domestic and foreign enterprises including Harbin Yuheng Pharmaceutical/Hefei Yifan) and Yichang Dongyangguang
.
The 81 varieties will be divided into 6 purchase groups of mealtime human insulin, basal human insulin, premixed human insulin, mealtime insulin analogues, basal insulin analogues, and premixed insulin analogues
.
Enterprises in each procurement group that meet the qualifications for declaration shall declare according to the quotation unit, and there are a total of 11 quotation units
.
It is understood that these types of participating in centralized procurement are all marketed drugs that have obtained valid domestic registration approvals before November 14, 2021 (inclusive), and their quality meets the standards of relevant national departments.
Products produced in accordance with the requirements of relevant departments are eligible to participate.
This round of national mining
.
In addition, companies participating in the bidding also need to meet the requirements of this centralized procurement in terms of quality standards, production capacity, supply stability, and corporate credit
.
Zhongtai Securities mentioned in a research report that the bidding and quantity rules have fully borrowed some rules from the centralized procurement of chemical drugs and the centralized procurement of insulin in Wuhan, and at the same time fully considers the actual production capacity of the company to avoid some companies from paying less than the cost.
Malicious declaration of prices
.
In addition, according to the research report issued by Dongguan Securities, the 81 varieties collected this time, specifically, there are 43 second-generation insulins, accounting for 53%, and 38 third-generation insulins, accounting for 47%.
Mixed insulin product group (there are 18 varieties), the least is the two product groups of basal insulin and premixed insulin analogues, both have only 12 varieties
.
From a corporate perspective, local and foreign companies are basically the same, with 41 local companies and 40 foreign companies
.
This also means that in this centralized procurement, domestic insulin varieties will have fierce competition with imported varieties, among which the competition of second-generation and third-generation insulin may be more intense
.
According to data from Meinenet, the sales of terminal insulin and similar drugs in China's public medical institutions in 2020 will be close to 27 billion yuan, of which Novo Nordisk, Sanofi, and Eli Lilly have a combined market share of more than 70%
.
Among domestic pharmaceutical companies, Ganli Pharmaceutical, Tonghua Dongbao, United Laboratories, etc.
are the leading companies.
Among them, Ganli Pharmaceutical's insulin market share will exceed 10% in 2020
.
The industry generally believes that with the implementation of centralized insulin procurement, the market structure may be rewritten, foreign-funded companies no longer occupy most of the market share, and domestic insulin-based leading companies may benefit
.
For diabetic patients, the base of diabetic patients in China is very large.
Data shows that the number of diabetic patients in China has reached 129 million, accounting for about 10% of China's total population
.
As an important drug for the treatment of diabetes, the price of insulin is expected to be further reduced after collective procurement negotiations, which will reduce the burden of drug costs for diabetic patients
.
